News

Article

ZEISS VISULAS Combi availability expands to Canada

Author(s):

Key Takeaways

  • ZEISS VISULAS Combi integrates photodisruption, photocoagulation, and slit lamp technology, enhancing clinical efficiency and patient experience.
  • The device eliminates patient relocation, streamlining workflow with custom modules and a uniform interface.
SHOW MORE

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution.

(Image Credit: AdobeStock/Postmodern Studio)

(Image Credit: AdobeStock/Postmodern Studio)

ZEISS Medical Technology announced the availability of its ZEISS VISULAS Combi, an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution, in Canada. The treatment is designed for retina, cataract, and glaucoma conditions, streamlining workflow with custom modules, a uniform interface, and space-saving features.

ZEISS VISULAS Combi also does not require the relocation of the patient, minimizing time-consuming changes and enhancing both clinical efficiency and the patient experience. "As an ophthalmologist committed to delivering the best possible care for my patients, I am excited to see the ZEISS VISULAS Combi in practice,” Hady Saheb, president of the Canadian Glaucoma Society, said. “I had the opportunity to use the SLT component in conjunction with the ZEISS FORUM and Imaging Solution, and the experience was seamless. The ability to generate treatment reports automatically—without the need to manually enter every detail—is a time-saver for those using the ZEISS FORUM and Imaging Solution.”

Now expanded into Canada as a result of Health Canada’s approval of ZEISS VISULAS Combi, staff from ZEISS Canada are excited to see the benefits of its expansion. Abrar Espop, head of medical technology at ZEISS Canada, said, “At ZEISS, we are committed to advancing ophthalmic care by improving clinical efficiency and supporting innovation and education. The ZEISS VISULAS Combi embodies our dedication to empowering clinicians and shaping the future of ophthalmology. With its multi-disciplinary capabilities, the ZEISS VISULAS Combi allows ophthalmologists to see more, do more, and treat more—all with one device. Previously, this would have required multiple systems, additional training, and larger workspaces. This platform represents a future-proof investment for ophthalmologists that provides precision and adaptability in one streamlined system.”

The new treatment from ZEISS will set a new standard in ophthalmic care, helping simplify the complexities of modern eye conditions and care while keeping patient satisfaction and comfort in mind.

Reference:
  1. ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care. Carl Zeiss Meditec AG. Accessed March 24, 2025. ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care
Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.